The Impact of Body Mass Index (BMI) on Clinical Outcomes for Patients Receiving Systemic Anti-Cancer Therapies for Advanced Clear Cell Renal Carcinoma.

John Greene, Zhe Wang, Benjamin H L Harris, David Dodwell, Simon R Lord

Abstract read

In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).ESMO real world data and digital oncology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John GreeneNuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0001-9400-5221

Zhe WangNuffield Department of Population Health, University of Oxford, Oxford, UK.

Benjamin H L HarrisComputational Biology and Integrative Genomics Lab, Department of Oncology, University of Oxford, Oxford, UK.

David DodwellNuffield Department of Population Health, University of Oxford, Oxford, UK.

Simon R LordComputational Biology and Integrative Genomics Lab, Department of Oncology, University of Oxford, Oxford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionObesity is a risk factor for the development of renal cell carcinoma (RCC), however observational studies have suggested patients with RCC receiving systemic anti-cancer therapy (SACT) and BMI ≥25 kg/m

Indexed as

Antineoplastic AgentsBody Mass IndexCarcinoma, Renal CellKidney NeoplasmsObesityAdultAgedAged, 80 and overFemaleHumansIndazolesMaleMiddle AgedPrognosisPyrimidinesRetrospective StudiesAntineoplastic AgentsIndazolespazopanibPyrimidinesSulfonamidesSunitinibBMIcancerobesity

Identifiers

PMID40098278

DOI10.1177/10732748251317681

PMCPMC11915284

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.